PRESS RELEASE · PRESS RELEASE · PRESS RELEASE
Neovacs will attend the 2016 European Smallcap Event
April 11 & 12, 2016
Paris, March 21, 2016 - NEOVACS (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, will be pleased to meet investors during:
The 2016 European Smallcap Event
April 11 & 12, 2016 - Palais Brongniart, Paris (France)
For more details on the event: http://www.midcapevents.com/small2016/home/
__________
Financial Calendar for Neovacs:
April 13th, 2016: Shareholders' AGM
October 14th, 2016: 2016 Half-Year results
Neovacs shares are eligible for the French tax incentivized PEA-PME
Neovacs is listed on Alternext Paris - ISIN: FR0004032746
About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNalpha-Kinoid, an immunotherapy being developed for the indication of lupus. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.
All information about Neovacs is available on the website: www.neovacs.fr
Contacts
Neovacs/ Charlène Masson
+33 (0)1 53 10 93 00
cmasson@neovacs.com
New Cap /Valentine Brouchot / Pierre Laurent
+33 (0)1 44 71 94 94
neovacs@newcap.eu
